Early research (Phase 1)WithdrawnNCT03506802
What this trial is testing
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma
Who this might be right for
HLA-A*0201 Positive Cells PresentNY-ESO-1 Positive Tumor Cells PresentRecurrent Plasma Cell Myeloma+1 more
Jonsson Comprehensive Cancer Center